Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Fund Letter | Thomas Küpfer (CIO), Moritz Solèr (CEO)LLOYD Capital - Focused Equity Strategy | Life Sciences Tools & ServicesLife Sciences Tools & Services | Long TMO (Thermo Fisher Scientific Inc.) Thermo Fisher Scientific was the largest contributor (+2.0 percentage points), with the stock up 34.7%. After several years... | BULL | View Pitch → | |
| Nov 9, 2026 | Fund Letter | Harry Burn, III; John P. DeGulis; T. Gibbs Kane, Jr.The Sound Shore Fund | Life Sciences Tools & ServicesLife Sciences Tools & Services | Long TMO (Thermo Fisher Scientific, Inc.) A new addition to the portfolio and our top performer for the quarter was Thermo Fisher Scientific (Thermo), a leading life sciences tool and lab equipment supplier that we have owned successfully in the past. We purchased the... | BULL | View Pitch → | |
| Oct 30, 2026 | Fund Letter | Cooper Investors Pty LimitedCooper Investors Global Equities Fund (Unhedged) | Life Sciences Tools & ServicesLife Sciences Tools & Services | Long TMO (Thermo Fisher Scientific Inc.) The Compounding Capital pool is well diversified across businesses in industries enjoying positive tailwinds, such as live entertainment and sports content (e.g. Liberty Media (FWONK) owner of Formula One and MotoGP), Life Sciences (e.g. Thermo Fisher (TMO)), Semiconductors (e.g. Taiwan Semiconductor Manufacturing Co (2330)) and US Industrial activity (e.g. RB Global (RBA)). | BULL | View Pitch → | |
| Oct 14, 2026 | Fund Letter | Neal KaufmanBaron Health Care Fund | Life Sciences Tools & ServicesLife Sciences Tools & Services | Long TMO (Thermo Fisher Scientific Inc.) Thermo Fisher Scientific Inc. is a global life sciences company offering analytical instruments, laboratory products, biopharmaceutical services, and specialty diagnostics. Shares rose on... | BULL | View Pitch → | |
| Oct 12, 2026 | Fund Letter | Emerald Wealth Partners Focused Equity Strategy | Life Sciences Tools & ServicesLife Sciences Tools & Services | Long TMO (Thermo Fisher Scientific Inc.) Thermo Fisher Scientific was the largest contributor (+2.0 percentage points), with the stock up 34.7%. After several years... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | Sydney Van VierzenEdgePoint Global | Life Sciences Tools & ServicesLife Sciences Tools & Services | Long TMO (Thermo Fisher Scientific Inc.) This is an image of an Orbitrap™ Astral™ Zoom Mass Spectrometer, a high-resolution instrument used to analyze small molecules essential to scientific research. It's made by... | BULL | View Pitch → | |
| Jan 27, 2026 | Fund Letter | Neal KaufmanBaron Health Care Fund | Life Sciences Tools & ServicesLife Sciences Tools & Services | Baron Health Care Fund 2025 Q4 (TMO) We added to the position in Thermo Fisher Scientific Inc., a life sciences tools company offering instruments, consumables, and bioproduction services. End markets for... | BULL | View Pitch → | |
| Jan 23, 2026 | Fund Letter | Achilleas TaxildarisThe Bristol Gate U.S. Equity Strategy | Life Sciences Tools & ServicesLife Sciences Tools & Services | The Bristol Gate U.S. Equity Strategy 2025 Q4 (TMO) Thermo Fisher Scientific's (TMO) foundation for the Q4 rally, hitting a new 52-week high in late December, started with a strong Q3 earnings release near the end of October that were ahead of consensus expectations. TMO reported pharma... | BULL | View Pitch → | |
| Jan 23, 2026 | Fund Letter | Sydney Van VierzenEdgePoint Global | Life Sciences Tools & ServicesLife Sciences Tools & Services | EdgePoint Global 2025 Q4 (TMO) Thermo Fisher Scientific was added aggressively during the market volatility leading up to and following Liberation Day, as the shares sold off materially despite no meaningful change in the underlying business. Following its 2006... | BULL | View Pitch → | |
| Jan 8, 2026 | Fund Letter | Renaissance Investment ManagementRenaissance Investment Management - Large Cap Growth | Life Sciences Tools & ServicesLife Sciences Tools & Services | Renaissance Investment Management - Large Cap Growth 2025 Q2 (TMO) Thermo Fisher was another notable underperformer, declining sharply during the quarter despite reporting solid operating results. The company lowered... | BULL | View Pitch → | |
| Nov 29, 2025 | Fund Letter | Achilleas TaxildarisThe Bristol Gate U.S. Equity Strategy | Life Sciences Tools & ServicesLife Sciences Tools & Services | The Bristol Gate U.S. Equity Strategy 2025 Q3 (TMO) Thermo Fisher's stock climbed 9% following better-than-expected Q2 2025 results, with revenue of $10.85B versus $10.68B consensus and EPS of $5.36/share versus $5.22/share. Organic growth of... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.